SpringWorks Therapeutics, Inc. (SWTX)

45,11 +1,76 (+4,06 %) À la clôture : 04:00PM EDT

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490
https://www.springworkstx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 305

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Francis I. Perier Jr., M.B.A.	Chief Financial Officer	768,24k	S.O.	1960
Dr. Badreddin Edris Ph.D.	Chief Operating Officer	1,02M	S.O.	1987
Dr. James Cassidy M.D., Ph.D.	Chief Medical Officer	904,25k	S.O.	1960
Mr. Michael P. Nofi	Chief Accounting Officer	S.O.	S.O.	1971
Mr. Tai-An Lin Ph.D.	Chief Scientific Officer	S.O.	S.O.	S.O.
Ms. Kim Diamond	Vice President of Communications & Investor Relations	S.O.	S.O.	S.O.
Mr. Herschel S. Weinstein J.D.	General Counsel & Secretary	568,64k	S.O.	1957
Mr. Daniel J. Pichl	Chief People Officer	428,51k	S.O.	1984
Mr. Bhavesh Ashar M.B.A.	Chief Commercial Officer	729,62k	S.O.	1966

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Gouvernance d’entreprise

L’ISS Governance QualityScore de SpringWorks Therapeutics, Inc. en date du 1 mai 2024 est 9. Les scores principaux sont Audit : 4; Société : 9; Droits des actionnaires : 8; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.